throbber
CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`
`APPLICATION NUMBER:
`
`203214Orig1s000
`
`
`CROSS DISCIPLINE TEAM LEADER REVIEW
`
`

`

`Cross-Discipline Team Leader Review
`
`
`Date
`July 20, 2012
`From
`Sarah Yim, M.D.
`m_ Cross-Disci line Team Leader Review
`NDA/BLA #
`NDA 203214
`
`Su n lement#
`
`
`
`Date of Submission
`
`PDUFA Goal Date
`
`October 21, 2011
`
`Au st 21, 2012
`
`Proprietary Name /
`Established S names
`
`Xeljanz/Tofacitinib
`
`Dosa_e forms / Stren_ h
`
`5 and 10 mo immediate-release tablets
`
`Proposed Indication(s)
`
`Recommended:
`
`. Treatment of Adult Patients with Moderately to
`Severely Active Rheumatoid Arthritis (RA) and
`Inadequate Response to One or More Disease-
`Modifying—Anti—Rheumatic Drugs ODMARDs)
`A roval, with Revisions to Pralosed Label
`
`1. Introduction
`
`New Drug Application (NDA) 203214 from Pfizer for the new molecular entity (NME)
`tofacitinib (also known as CP-690,550), an oral small molecule inhibitor of the Janus
`associated kinases (JAK) being proposed for the treatment of adult patients with moderately to
`severely active rheumatoid arthritis who have had inadequate response to one or more disease-
`modifying anti-rheumatic drugs (DMARDs). The product is being proposed as immediate-
`release tablets for oral administration in 5 and 10 mg dosage strengths. Pfizer proposes the
`recommended starting dose as 5 mg twice a day, with an added qualifier that some patients
`may benefit from an increase to 10 mg twice a day based on clinical response.
`
`In kinase assays, tofacitinib inhibits JAKl, JAK2, JAK3 and, to a lesser extent, TyK2. In the
`immune system, JAKl, JAK2, and TyK2 are ubiquitously expressed, whereas JAK3
`expression is restricted to hematopoietic cells. JAKl knockout mice display perinatal lethality
`(thought to be related to neuroapoptosis due to lack of gpl30 signaling), and JAKl inhibition
`would be expected to enhance susceptibility to infections by viruses and bacteria related to
`defective signaling by class II cytokine receptors and receptors that use the gp130 subunit.
`JAK2 has a pivotal role in the signal transduction required in definitive erythropoiesis and
`JAK2 knockout mice are embryonically lethal due to a lack of erythropoesis. TyK2 knockout
`mice are viable with no overt abnormalities, but do show reduced CD4+ cell diflerentiation to
`Th1 cells. JAK3 knockout mice display T and B cell lymphopenia without effects on myeloid
`lineage cells. Autosomal recessive JAK3 deficiency in hmnans results in a form of severe
`
`Reference ID: 31 62509
`
`Page 1 of 53
`
`

`

`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`combined immunodeficiency disease (SCID) that is characterized by lack of circulating T cells
`and NK cells, but a normal number of B-cells.1
`
`If approved, tofacitinib would be the first JAK inhibitor for rheumatoid arthritis (RA), and the
`first orally administered agent approved since leflunomide’s approval in 1998. However, one
`other JAK inhibitor, ruxolitinib, has been approved since November 2011 for myelofibrosis
`indications. The NDA for tofacitinib posed a number of review issues which will be the focus
`of this memorandum. These issues include:
`• Whether the submitted data are adequate to conclude that tofacitinib is a disease-modifying
`agent for RA and if the conclusion applies to both proposed doses (5 and 10 mg BID)
`• What the most pressing safety concerns are for tofacitinib, and whether there is a dose or
`exposure related increase in risk for these concerns.
`
`
`These issues, and the overall benefit-risk profile of tofacitinib, were discussed at a meeting of
`the Arthritis Advisory Committee on May 9, 2012. Highlights of this discussion are
`summarized in Section 9, below.
`
`
`2. Background
`
`
`Rheumatoid Arthritis (RA) has been the prototypical autoimmune disease for drug
`development; especially since the late 1990s with the success of the targeted biologic
`therapies. It is a chronic, inflammatory polyarthritis affecting approximately 1% of adults
`worldwide, approximately 75% of whom are women. The majority of patients would have
`persistent, progressive disease which would result in increasing disability, if untreated.2
`Fortunately, many effective treatments have been developed and approved for RA, as
`summarized in Table 1 below.
`
`
`
`1 L Vijayakrishnan, R Venkataramanan, and P Gulati, “Treating inflammation with the Janus Kinase inhibitor CP-
`690,550.” Trends Pharmacol Sci 2011 Jan; 32(1):25-34.
`2 SL Scott and S Steer, “The course of established rheumatoid arthritis,” Best Practice & Research Clinical
`Rheumatology 2007, 21(5):943-967
`
`Reference ID: 3162509
`
`Page 2 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`Table 1 FDA Approved Drugs and Biologics for RA
`
`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`
`
`
`Since the late 1990’s, clinical development programs evaluating the efficacy of proposed
`products for RA have primarily utilized American College of Rheumatology (ACR) response
`criteria to assess treatment effect on signs and symptoms, the Health Assessment
`Questionnaire-Disability Index (HAQ-DI) to assess treatment effect on physical functioning,
`and a standardized radiographic scoring system, such as the Sharp Score or modifications
`thereof, to assess treatment effect on structural damage progression. These outcome measures
`will be described in greater detail later in this memorandum.
`
`One conundrum associated with the assessment of efficacy in RA is the possible dissociation
`between clinical and radiographic outcomes. Radiographic progression may occur in people
`who have very low apparent disease activity and patients with clinical disease activity may
`have no evidence of radiographic progression.3 Thus, documentation of a benefit of treatment
`on structural damage progression has been an important goal of clinical development programs
`for new products proposed for RA, particularly if the product has a novel target. This has
`become an increasingly important aspect of the risk-benefit assessment for new RA treatments
`in light of the many approved treatments that have documented beneficial effects in inhibiting
`structural damage progression.
`
`Relevant Regulatory History for Tofacitinib in RA
`
`At the time the investigational new drug application (IND) for tofacitinib was submitted,
`Phase 1 clinical data were already available. Dose-ranging study A3921019 was the initial
`protocol submitted to the IND, which proposed monotherapy with tofacitinib at doses of 5, 15,
`and 30 mg BID for a duration of 6 weeks. Lack of nonclinical coverage for the proposed
`doses was noted at that time. However, because there were pre-existing human data in
`approximately 180 patients at doses up to 50 mg BID for 14 days, the Agency at that time
`made an internal decision that the clinical data were adequate to support the safety of
`
`
`3 EC Keystone, “Clinical implications of understanding radiographic findings in relation to clinical outcomes in
`rheumatoid arthritis.” J Rheumatol 2009; 36 Supple 82:11-16
`
`Reference ID: 3162509
`
`Page 3 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE H/DPARP
`
`NDA 203214: Tofacitinib for RA
`Pfizer. Inc.
`
`proceeding with the study, despite the lack of nonclinical support for all of the proposed doses,
`which would typically be required.
`
`In January 2007, the Agency provided written feedback regarding the proposed design of
`Study A3921025 and an extension study. Study A3921025 included proposed doses of l_, 3, 5,
`10, 15 mg BID and 20 mg QD, to be given with stable background methotrexate (MTX) for a
`duration of 6 months. The design of the study was considered generally acceptable, although
`it was noted that the nonclinical data appeared to only support chronic dosing in patients 11p to
`5 mg BID. The review team at that time determined that previous clinical experience appeared
`to support the ability to proceed with the proposed study.
`
`0
`
`In December 2008, an End of Phase 2 (EOP2) meeting took place to discuss the tofacitinib
`development program. The Agency generally agreed with the proposed Phase 3 program
`elements and endpoints. Discussions included:
`0 Pure placebo control should be limited to 3 months, even if patients had apparent
`symptomatic improvement (i.e., ACR20).
`5 mg BID and 10 mg BID doses appear reasonable; 3 mg BID should be considered. QD
`regimens may warrant further study.
`0 The safety database proposal appeared to be adequate (1500 patients on the to—be—marketed
`dose for a year or more).
`0 Concern regarding effects on lipids and the implications for cardiovascular safety, and the
`need for this to be comprehensively evaluated for NDA.
`
`At the Pre-NDA meeting for this application in February 2011, general agreement was reached
`on the proposed format and content of NDA, and the adequacy (to support review of the
`application) of the nonclinical program and clinical safety database.
`
`M0
`
`3. CMC/Device
`
`CMC Reviewers: Craig Bertha, Ph.D.,' Donghao Lu, Ph.D., Ying Wang, PII.D., Bogdan
`Kurtyka, Ph.D.,' Supervisory: Eric Dufijz, PILD.
`
`0 General product quality considerations
`
`The drug substance tofacitinib citrate (CP—690,550-10) is a white to off-white
`that is
`
`"'""
`
`M0
`
`Tofacitinib citrate is highly soluble as per
`the Biophannaceutics Classification System and the applicant indicates that it has low
`permeability (BCS class 3). The structure of tofacitinib citrate includes an arylamine flmction,
`which is a structural alert for mutagenicity. The drug substance is not photosensitive and the
`
`Reference ID: 31 62509
`
`Page 4 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim. M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`NDA 203214: Tofacitinib for RA
`Pfizer. Inc.
`
`(me, as well as the
`stability data provided supports both the proposed retest period of
`post-approval stability protocol proposed. The drug substance is manufactured at Pfizer
`Ireland Pharmaceuticals, Ringaskiddy, Ireland. It is packaged in
`(hm
`
`(IN)
`
`supported.
`
`and retest period of
`
`(I!) (4) l
`
`s
`
`The drug product immediate release tofacitinib tablets are formulated as fihn—coated round
`tablet. Two strengths, 5 mg and 10 mg, are proposed for commercialization. The strengths of
`the drug products are based on the equivalent amount of tofacitinib. The 5 mg tablets are white
`to off-white, fihn—coated, round tablets debossed with “Pfizer” on one side and “JKIS” on the
`other side.
`M0
`mm
`
`The tablets are manufactured with a
`
`(b) (4)
`
`The drug product
`is packed in high-density polyethylene (HDPE) bottles with desiccant and closures with
`induction seal liners. The drug product is manufactured and packaged in Frieburg, Germany
`and is also being packaged in Puerto Rico. The submitted drug product stability data include
`12 months at long term storage condition of 25°C/60%RH and 6 month accelerated storage
`condition of 40°C/75%RH for 3 batches of each strength. The stability data supports the
`proposed 24 month shelf life for the drug product when stored at the proposed 20°C to 25°C
`(68°F to 77°F),
`W"
`
`0 Facilities review/inspection
`
`At the time of this review, the Establishment Evaluation Request (EER) is still pending.
`
`0 Other notable issues (resolved or outstanding)
`
`From a Chemistry, Manufacturing, and Controls (CMC) perspective, the application is
`recommended for approval pending an acceptable recommendation from the Office of
`Compliance regarding the facilities’ inspections. No CMC Phase 4 commitments are
`recommended.
`
`4. Nonclinical Pharmacology/Toxicology
`
`Pharm-Tox Reviewer: Lawrence S. Leshin, D. VM, Ph.D.,' Supervisor: Molly Shea, PhD.
`
`0 General nonclinical pharmacology/toxicology considerations
`
`Pivotal nonclinical toxicology studies were conducted in rats (6-month, doses of 0, l, 10, 100
`mg/kg/day) and cynomolgus monkeys (9-month, doses of 0, 0.5, 2, 10 mg/kg/day, 4 monkeys
`per sex per group). No-Observed-Adverse—Effect-Levels (NOAELs) could not be determined
`as adverse effects were noted in each of the lowest doses tested. Toxicities were associated
`
`Reference ID: 31 62509
`
`Page 5 of 53
`
`

`

`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`with suppression of the immune and hematopoietic systems, to include suppression of myeloid
`and erythroid bone marrow production, reductions in circulating red and white blood cells,
`increased bacterial infections, and reduced or atrophied lymphoid organs. Reversibility of
`these findings was not evaluated in the chronic toxicity studies. However shorter duration
`repeat-dose toxicity studies in rats and monkeys demonstrated that these findings were at least
`partially reversible.
`
`In the nonclinical program, including shorter (i.e. 1 to 1.5 month) studies, adverse effects
`resulting in mortality included:
`•
`in rats, bacterial infections of the kidney, lung alveolar histiocytosis and interstitial
`inflammation
`in monkeys, lymphomas, and bacterial and viral infections
`
`•
`
`In the 9-month (39-week) chronic toxicology study in cynomolgus monkeys, three monkeys in
`the high dose group (10 mg/kg/day) developed lymphomas. Pfizer concluded that these
`lymphomas were consistent with gamma herpes-virus induced lymphoproliferative disorder
`associated with immunosuppression. Additional details are discussed in the context of the
`human lymphoma findings in the RA and renal transplant settings in the safety section of this
`memorandum.
`
`
`• Carcinogenicity
`
`
`Tofacitinib was not mutagenic or genotoxic based on in vitro and in vivo tests for gene
`mutations, chromosomal damage, and DNA damage. Carcinogenicity was assessed in a 6-
`month mouse study and a 2-year rat study. The mouse study did not suggest oncogenic
`potential related to tofacitinib. The rat study neoplastic findings included interstitial cell
`adenomas of the testes, and benign thymomas and malignant hibernomas in females.
`
`
`• Reproductive toxicology
`
`
`In reproductive toxicology studies, tofacitinib did not appear to affect the fertility of male rats,
`but decreased pregnancy rate, numbers of corpora lutea, implantation sites, and viable fetuses
`in female rats, with an increase in early resorptions, pre-implantation loss and post-
`implantation loss. Tofacitinib was teratogenic (visceral and skeletal abnormalities) in rats and
`rabbits.
`
`
`• Other notable issues (resolved or outstanding)
`
`
`The Pharmacology/Toxicology team believes the information in this application is adequate to
`support approval. However they also recommend that the male fertility study and the juvenile
`rat study be performed again using a revised design:
`1. In the male fertility study, males were administered tofacitinib for at least 63 days,
`but matings occurred after 1 month of treatment, an insufficient duration of drug
`exposure for a complete spermatogenic cycle. Therefore, at least the study in adult
`males should be repeated and conducted in accordance with ICH5(R2).
`
`Reference ID: 3162509
`
`Page 6 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`
`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`2. In the juvenile rat study, both males and females were administered CP-690550
`from weaning on day 21 until near or at puberty in the female, and in the male
`through expected puberty for an appropriate duration of exposures in both sexes.
`However, they were not mated until a few weeks after drug dosing stopped,
`allowing for recovery of any potentially adverse effects on fertility. The study in
`juvenile animals was not required, but if done correctly, could be incorporated into
`labeling to provide safety for treatment of pediatric patients with regards to
`reproductive maturation and fertility. These differ from classic segment 3 postnatal
`studies in that in the segment 3 studies the juvenile animals are not dosed with
`drug, only the dams are dosed, and the juvenile are followed to see if there are
`generational effects of the drug. The study in juvenile rats incorporates drug
`administration directly to the juvenile animals. This is an optional study, but if
`conducted, should also be designed and evaluated as recommended in ICH5(R2).
`
`
`
`5. Clinical Pharmacology/Biopharmaceutics
`
`
`Clinical pharmacology reviewer: Lokesh Jain, Ph.D.; Supervisor: Suresh Doddapaneni, Ph.D.
`Pharmacometrics reviewer: Lokesh Jain, Ph.D. and Atul Bhattaram, Ph.D.; Supervisor: Atul
`Bhattaram, Ph.D.
`Pharmacogenomics reviewer: Jeffrey Kraft, Ph.D.; Supervisor: Michael Paconowski,
`Pharm.D., M.P.H.
`
`
`• General clinical pharmacology/biopharmaceutics considerations, including
`absorption, metabolism, half-life, food effects, bioavailability, etc.
`
`
`The absolute bioavailability of tofacitinib at the 10 mg dose was 74%. The systemic exposure
`(AUC0-∞) and peak plasma concentration (Cmax) increased in proportion to dose in the dose
`range of 1 to 100 mg. Tmax was reached by approximately 0.5-1 hours following oral
`administration. Coadministration with food had no significant effect on the extent of
`absorption (AUC0-∞) but rate of absorption (Cmax) was reduced by 32%. Upon multiple
`dosing, steady-state was reached by 24-48 hours with negligible accumulation. Tofacitinib is a
`substrate of P-gp transporter.
`
`Tofacitinib has a total plasma protein binding of approximately 39%. Tofacitinib binds
`moderately to albumin and does not bind to alpha-1 acid glycoprotein. Steady-state volume of
`distribution (Vdss) for tofacitinib following intravenous infusion administration was 87 L,
`suggesting distribution into tissues.
`
`Tofacitinib was extensively metabolized by the liver; primarily by CYP3A4 enzyme with
`minor contribution from CYP2C19. All metabolites comprise less than <8% of total drug
`exposure and their potency was reported to be <10% of the potency of tofacitinib for JAK1/3
`inhibition. Based on in vitro studies, tofacitinib is not a substrate of BCRP transporter. Based
`on in vitro studies, at therapeutic concentrations, tofacitinib has low potential for induction or
`
`Reference ID: 3162509
`
`Page 7 of 53
`
`

`

`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`inhibition of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4 metabolic enzymes and low potential
`of inhibition for P-gp, OCT2, OATP1B1, OATP1B3.
`
`Of the 94% drug recovered following oral administration in a mass balance study,
`approximately 29% and 51% was recovered in urine as parent drug and metabolites,
`respectively. In feces, proportion of parent and metabolites recovered was approximately 1%
`and 13%. The terminal elimination half-life of tofacitinib was approximately 3 hours after
`single- or multiple-dose administration.
`
`
`• Drug-drug interactions
`
`
`Tofacitinib coadministration with a strong CYP3A inhibitor, ketoconazole, increased the mean
`tofacitinib AUC (90%CI) by 103% (91%, 116%) and Cmax by 16% (5%, 29%).
`When coadministration with a strong CYP3A4 inhibitor is necessary, the clinical
`pharmacology team recommends a dose reduction as follows:
`•
`If 10 mg BID is an approved dose, then the dose with concomitant administration should
`not exceed 5 mg BID.
`If 5 mg BID is the limit, then a reduced dose of 5 mg QD is recommended.
`
`•
`
`Coadministration with a moderate CYP3A4 and strong CYP2C19 inhibitor, fluconazole,
`increased mean tofacitinib AUC (90%CI) by 79% (64%, 96%) and Cmax by 27% (12%, 44%).
`Thus the same dose reduction recommendation applies for moderate CYP3A4 and strong
`CYP2C19 inhibitors.
`
`Tofacitinib coadministration with a strong CYP3A inducer, rifampin, resulted in substantial
`decreases in mean tofacitinib AUC (90%CI) by -84% (-86%, -82%) and in Cmax by -74% (-
`77%, -69%). Coadministration with rifampin is not recommended because that may result in
`ineffective concentrations of tofacitinib.
`
`Coadministration with tacrolimus, a CYP3A substrate with narrow therapeutic index,
`increased mean (90%CI) tofacitinib AUC (90%CI) by 21% (13%, 30%) and decreased Cmax
`by -9% (-17%, -1%). Coadministration with cyclosporine, a CYP3A substrate with narrow
`therapeutic index and also an inhibitor of P-gp increased mean (90%CI) tofacitinib AUC
`(90%CI) by 73% (62%, 85%) and decreased Cmax by -17% (-29%, -3%). The clinical
`pharmacology team raised concerns regarding a possible pharmacodynamic interaction with
`the tofacitinib and either tacrolimus or cyclosporine and recommended the two drugs not be
`coadministered. However, immunosuppressive drugs are not uncommonly combined based on
`the clinical judgment of the healthcare professional for the particular clinical scenario, and I
`would not recommend labeling specifically prohibiting coadministration on the basis of a
`concern for pharmacodynamic interaction alone.
`
`Coadministration with methotrexate, had no significant effect on tofacitinib exposure and no
`dose adjustment is needed for tofacitinib when coadministered with methotrexate. Tofacitinib
`had no substantial effects on the plasma levels of oral contraceptives (ethinylestradiol and
`levonorgestrel), midazolam (CYP3A substrates), or methotrexate, thus no dose adjustment is
`needed for these drugs when coadministered with tofacitinib.
`
`Reference ID: 3162509
`
`Page 8 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`
`
`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`• Intrinsic factors potentially affecting elimination: age, gender, hepatic
`insufficiency and renal impairment
`
`
`There was no substantial impact of age, weight, and gender on PK parameters, after
`accounting for differences in renal function (i.e., creatinine clearance).
`
`For subjects with mild, moderate and severe renal impairment, mean percentage change in
`AUC (90%CI), compared to subjects with normal renal function were respectively: 41% (-5%,
`109%), 71% (14%, 157%), and 156% (69%, 287%). Mean percentage changes in Cmax (90%
`CI) for these cases were respectively: 1% (-31%, 49%), 2% (-31%, 52%), and 21% (-19%,
`81%). Based on these data, the clinical pharmacology team recommends dose reduction (as
`described above) of tofacitinib in patients with moderate and severe renal impairment.
`
`For subjects with mild and moderate hepatic impairment, mean percentage change in AUC
`(90%CI), compared to subjects with normal hepatic function were respectively: 3% (-22%,
`36%) and 65% (25%, 117%). Mean percentage change in Cmax (90% CI) for these cases
`were respectively: -1% (-25%, 32%) and 49% (12%, 97%). Based on these data, the clinical
`pharmacology team recommends dose reduction of tofacitinib for these patients. Tofacitinib
`was not evaluated in patients with severe hepatic impairment, but as tofacitinib is extensively
`hepatically metabolized, there is reason to believe that increased exposure, and risk, would
`occur in this population, and therefore use of tofacitinib in this population is not
`recommended.
`
`
`• Demographic interactions/special populations
`
`Based on available data are no major differences were seen in tofacitinib AUC and Cmax
`between White, Black and Asian patients, after accounting for differences in renal function
`(i.e., creatinine clearance). However, population PK analysis in RA patients showed 43%
`lower apparent clearance in RA patients relative to a healthy adult.
`
`
`• Thorough QT study
`
`
`QT effect was evaluated in a randomized, blinded, crossover, single-dose study, in which
`60 healthy subjects received a supra-therapeutic tofacitinib dose of 100 mg, placebo, and
`moxifloxacin 400 mg. The washout duration between treatment periods was 7 days. No
`significant QT prolongation effect was detected at the tested 100 mg tofacitinib dose. The
`largest upper bounds of the 2-sided 90% CI for the mean difference between CP-690,550
`100 mg and placebo were below 10 ms, the threshold for regulatory concern as described in
`the ICH E14 guideline.
`
`
`• Other notable issues (resolved or outstanding)
`
`
`
`Reference ID: 3162509
`
`Page 9 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`NDA 203214: Tofacitinib for RA
`Pfizer. Inc.
`
`The Office of Clinical Pharmacology has determined the information in NDA 203214
`acceptable. No outstanding issues have been identified or Phase 4 commitments
`recommended.
`
`6. Clinical Microbiology—MIA
`
`7. Clinical/Statistical- Efficacy
`
`Clinical Primary Reviewer: Niko/av Nikolov, MD.
`Statistical Reviewer: Yongman Kim, Ph.D., Statistical Team Leader: Joan Buenconsejo, PILD.
`
`Overview ofthe clinicalprogram
`
`Five randomized placebo-controlled trials have been submitted as the primary evidence of
`efficacy and safety of tofacitinib, as summarized in Table 2 below. As study numbers all
`begin with “A32,” they will at times be abbreviated by the last four digits of the study number.
`A single trial (1044) evaluated radiographic outcomes, a single trial (1064) included a control
`arm with the TNF inhibitor adalimumab, and a single trial (1045) evaluated tofacitinib
`monotherapy.
`
`Patients completing the Phase 3 trials had the option to enroll in open-label long-term
`extension @TE) studies. Study 1041 is an LTE for patients completing clinical development
`studies in Japan (Phase 2 studies 1039 and 1049, and Japanese participants in global Study
`1044). Study 1024 is the LTE for all other patients in the clinical development program.
`These studies allowed for 5 or 10 mg BID doses, to be adjusted as needed for either efficacy or
`safety reasons. Prior to amendment 3 (January 2009), all patients were initiated on 5 mg BID
`upon entry in the LTE. Subsequent to this, all patients (with exceptions in certain countries)
`have been initiated on 10 mg BID.
`
`(5) (4)
`
`Reference ID: 31 62509
`
`Page 10 of 53
`
`

`

`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`Table 2: Summary of the Phase 3 Studies in RA Submitted for the NDA
`
`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`
`
`Brief Description of Efficacy Endpoints
`
` •
`
`
`
` ACR Response Rates
`
`
`In 1995, the American College of Rheumatology (ACR) published a definition of
`improvement for clinical trials in rheumatoid arthritis, which have since been used in drug
`development trials to demonstrate evidence of efficacy for signs and symptoms of RA.4 The
`ACR20 response is calculated as a >20% improvement in:
`•
`tender joint count (of 68 joints) and
`• swollen joint count (of 66 joints) and
`• 3 of the 5 remaining ACR core set measures
`o Patient Global Assessment of Arthritis on a visual analog scale (VAS)
`o Physician Global Assessment of Arthritis on a VAS
`o Patient Assessment of Pain on a VAS
`o Patient Assessment of Physical Function (e.g. Health Assessment
`Questionnaire)
`o Acute Phase Reactant (Erythrocyte Sedimentation Rate or C-reactive
`protein)
`Fifty percent and 70 percent improvement (ACR50 and ACR70) are similarly calculated using
`these higher levels of improvement.
`
`
`4 DT Felson, et al., Arthritis & Rheum, 1995 June, 38(6):727-735
`
`Reference ID: 3162509
`
`Page 11 of 53
`
`

`

`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`• Health Assessment Questionnaire-Disability Index (HAQ-DI)
`
`The Agency has historically recognized a distinct claim in RA for “improvement in physical
`function” based on outcome measures such as the HAQ-DI.5 This instrument assesses a
`patient’s level of functional ability and includes questions pertaining to fine movements of the
`upper extremity, locomotor activities of the lower extremities, and activities that involve both
`upper and lower extremities. There are 20 questions in 8 categories of functioning which
`represent a comprehensive set of functional activities: dressing, rising, eating, walking,
`hygiene, reach, grip, and usual activities. Patients respond on a four-level difficulty scale
`ranging from zero (no difficulty) to three (unable to do). The 8 category scores are averaged
`into an overall HAQ-DI score on a scale from zero (no disability) to 3 (completely disabled).
`The most widely accepted figure on the minimal clinically important difference in the HAQ-
`DI score is an improvement (decrease) of at least 0.22 units.
`
` •
`
` Disease Activity Score (DAS)-28
`
`
`The DAS28 is a composite index of RA disease activity which incorporates the number of
`tender and swollen joints (out of 28 possible), a patient global assessment of disease activity
`(0-100 mm visual analog scale), and erythrocyte sedimentation rate (ESR) results.6 An
`alternative equation is available for use with c-reactive protein (CRP) results. These variables
`are summed and weighted mathematically into a single numerical value ranging from 0 to 10.
`Comparing the DAS28 and the ACR response criteria, beyond the differences in number of
`maximum tender or swollen joints counted (e.g. DAS28 does not include the joints of the feet),
`additional variables of physician global assessment, patient pain, and HAQ score are
`incorporated into the ACR response criteria. The DAS28 has additional utility in measuring
`the level of disease activity at a given timepoint, whereas the ACR response criteria are
`calculated as improvement in the variables over a set period of time. A DAS28 score >5.1 is
`indicative of high disease activity, and <3.2 of low disease activity. A score of <2.6 has been
`used to describe an even lower threshold of disease activity.
`
` •
`
` Radiographic Outcome: Van der Heijde modified Sharp Score
`
`
`The Van der Heijde-modified Sharp radiographic scoring method grades the presence of
`erosions in the joints of the hands and feet, and the presence of joint space narrowing (JSN) in
`the hands, wrists, and feet.7 The scores for each feature for the individual joints are summed.
`Erosions are assessed at 16 locations in each hand and wrists and 12 locations in each foot,
`using a 6-point scale from 0 to 5. Scores are derived based on the number and size of discrete
`erosions in each location, but are summed to a maximum of 5. Thus the maximum erosion
`score for the hands/wrists is 160, and the maximum erosion score for the feet is 120, for a
`maximum total erosion score of 280. JSN scores are based on 15 locations in each hand and
`
`5 B Bruce and JF Fries, “The Health Assessment Questionnaire (HAQ).” Clin Exp Rheumatol 2005; 23 (Suppl
`39):S14-S18
`6 J Fransen and PLCM van Riel, “The Disease Activity Score and the EULAR Response Criteria.” Clin Exp
`Rheumatol 2005; 23 (Suppl 39): S93-S99
`7 S Boini and F Guillemin, “Radiographic scoring methods as outcome measures in rheumatoid arthritis:
`properties and advantages.” Ann Rheum Dis 2001; 60:817-827
`
`Reference ID: 3162509
`
`Page 12 of 53
`
`

`

`
`
`
` NDA 203214: Tofacitinib for RA
`Pfizer, Inc.
`
`Cross Discipline Team Leader Review
`Sarah Yim, M.D.
`DHHS/FDA/CDER/ODE II/DPARP
`
`wrist and 6 locations in each foot, scored using a 5-point scale from 0 to 4: 0 = normal; 1 =
`focal or minimal and generalized narrowing; 2 = generalized narrowing <50%; 3 = generalized
`narrowing >50% or subluxation; and 4 = ankylosis or complete dislocation. The maximum
`total JSN for the hands/wrists is 120, and the maximum total JSN for the feet is 48, for a
`maximum total JSN score of 168. Therefore the theoretical maximum modified total Sharp
`Score (mTSS) is 448, although the actual clinical range in RA drug development trials is
`typically much lower because a given individual typically only has a fraction of his or her
`joints affected by radiographically evident damage.
`
`Dose selection
`
`The proposed recommended starting dose is 5 mg twice a day, with an added qualifier that
`some patients may benefit from an increase to 10 mg twice a day based on clinical response.
`Pfizer selected 5 and 10 mg BID doses of tofacitinib based on dose-response modeling of
`safety and efficacy data from Study 1025, with supportive data from Study 1019 and Study
`1035. The key design features of these studies and efficacy results for the American College
`of Rheumatology (ACR) Responses are summarized in Table 3 and Figure 1 below. On
`background methotrexate (MTX) in Study 1025, the dose response was very flat across the
`range of doses from 3 mg BID to 20 mg QD. There was some suggestion in Study 1035 (a
`monotherapy evaluation) that 10 mg BI

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket